Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704145 | 0.82 | CA4 (0.37) | CA4 | |
| SCHEMBL7096596 | 0.81 | ESR2 (0.46) | CA2CA1CA4CA14 | |
| SCHEMBL8113015 | 0.81 | CA1 (0.34) | CA2CA1 | |
| SCHEMBL27600931 | 0.80 | CA4 (0.46) | CA2CA1CA4CA7CA14 | |
| SCHEMBL17233741 | 0.78 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL20594005 | 0.78 | — | — | |
| SCHEMBL7424773 | 0.78 | MAOA (0.44) | — | |
| SCHEMBL6058734 | 0.78 | ALDH1A1 (0.37) | — | |
| SCHEMBL12919164 | 0.77 | CA1 (0.46) | CA2CA1 | |
| SCHEMBL3540870 | 0.77 | LTA4H (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | AVENTIS PHARMA S.A. | 2002-10-24 | — | — | US | disclosed |
| US-6448294-B1 | SUCH AS 1,5-DICHORO- OR 5-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL) SUBSTITUTED -6-(4-HYDROXYPHENYL)-2-NAPHTHALENOLS; ANTIUTERO-TROPHIC AND REPLACEMENT TREATMENT OF SYMPTOMS LINKED TO MENOPAUSE PARTICULARLY OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6365775-B1 | ANTIUTEROTROPHIC; TREATMENTS OF SYMPTOMS RELATED TO MENOPAUSE AND PREMENSTRAL SYNDRONE | AVENTIS PHARMA S.A. (FR) | 2002-04-02 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| US-6147119-A | TREATING HYPOFOLLICULINIA DISORDERS; ANTICARCINOGENIC, ANTIMETASTASIS AND ANTITUMOR AGENTS; PREMENSTRUAL TENSION, MENOPAUSE, OSTEOPOROSIS | HOECHST MARION ROUSSEL (FR) | 2000-11-14 | — | — | US | disclosed |
| US-5629428-A | 3-Chloropyridines, and their use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
| US-5562859-A | SWITCHING AND DISPLAY DEVICE | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-10-08 | — | — | US | disclosed |
| US-5445763-A | Ferroelectricity; switching and/or display devices containing outer plates, electrodes, at least one polarizer and one alignment layer | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | CA2 4562/4885CA1 3614/4885ENPP2 1608/4885 |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | SHBG, ESR2, CYP19A1 | CA2 1580/4885CA1 877/4885ENPP2 887/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | CA2 1881/4885CA1 1198/4885ENPP2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.